Association between atrial natriuretic peptide and cyclic GMP in hypertension and in chronic renal failure

Clinica Chimica Acta

Volumn 275, Issue 1, 1998, Pages 9-18

  Sagnella, G A ^a   Saggar Malik, A K ^a   Buckley, M G ^a   Markandu, N D ^a   Eastwood, J B ^a   MacGregor, G A ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

ANP; Chronic renal failure; Cyclic GMP; High blood pressure; Sodium

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKER; CYCLIC GMP;

ADULT; AGED; ARTICLE; ASSOCIATION; BLOOD LEVEL; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; CREATININE CLEARANCE; ESSENTIAL HYPERTENSION; FEMALE; GLOMERULUS FILTRATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; URINE LEVEL;

ADULT; AGED; AGED, 80 AND OVER; ATRIAL NATRIURETIC FACTOR; CYCLIC GMP; FEMALE; HUMANS; HYPERTENSION; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED;

EID: 0032490536     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-8981(98)00062-X     Document Type: Article

References (28)

1. [1] Koller KJ, Goeddel DV. Molecular biology of the natriuretic peptides and their receptors. Circulation 1992;86:1081-8.
2. [2] Zeidel ML. Renal actions of atrial natriuretic peptide: regulation of collecting duct sodium and water transport. Ann Rev Physiol 1990;52:747-59.
3. [3] Hamet P, Tremblay J, Pang SC, et al. Cyclic GMP as mediator and biological marker of atrial natriuretic factor. J Hypertens 1986;4(Suppl 2):s49-56.
4. [4] Jakob G, Mair J, Puschendorf B. Direct determination of cyclic guanosine monophosphate in plasma. Clin Chem 1993;39:2530-1.
5. [5] Hasegawa K, Matsushita Y, Inoue T, et al. Plasma levels of atrial natriuretic peptide in patients with chronic renal failure. J Clin Endocrinol Metab 1986;63:819-22.
6. [6] Shenker Y, Port FK, Swartz RD, et al. Atrial natriuretic hormone secretion in patients with renal failure. Life Sci 1987;41:1635-44.
7. [7] Suda S, Weidmann P, Saxenhofer H, et al. Atrial natriuretic factor in mild to moderate chronic renal failure. Hypertension 1988;11:483-90.
8. [8] Predel HG, Kipnowski J, Meyer LH, et al. Human atrial natriuretic peptide in non-dialyzed patients with chronic renal failure. Clin Nephrol 1989;31:150-5.
9. [9] Dussaule JC, Michel C, Wolf JP, et al. Atrial natriuretic factor and changes in dietary sodium intake in patients with chronic renal failure. Clin Sci 1990;78:327-34.
10. [10] Meyer LH, Bayer T, Predel HG, et al. Effects of atrial natriuretic peptide on systemic and renal hemodynamics and renal excretory function in patients with chronic renal failure. Klinische Wochenschrift 1991;69:895-903.
11. [11] Lettgen B, Bald M, Vallee H, et al. Atrial natriuretic peptide and cyclic 3′5′-guanosine monophosphate as indicators of fluid volume overload in children with chronic renal failure. Pediatr Nephrol 1992;6:60-4.
12. [12] Lauster F, Heim JM, Drummer C, et al. Plasma cyclic GMP level as a marker of the hydration state in renal replacement therapy. Kidney Int 1993;43(Suppl 41):s57-9.
13. [13] Broades AE, Kaminskyni NI, Hardman JG, et al. Kinetic parameters and renal clearances of plasma adenosine 3′5′-monophosphate and guanosine 3′5′-monophosphate in man. J Clin Invest 1970;49:2222-36.
14. [14] Hamet P, Stouder DA, Gim HE, et al. Studies of the elevated extracellular concentration of cyclic GMP in uremic man. J Clin Invest 1975;56:339-45.
15. [15] Sagnella GA, Markandu ND, Shore AC, et al. Effects of changes in dietary sodium intake and saline infusion on immunoreactive atrial natriuretic peptide in human plasma. Lancet 1985;ii:1208-11.
16. [16] Buckley MG, Sethi D, Markandu ND, et al. Plasma concentrations and comparisons of brain and atrial natriuretic peptides in normal subjects, cardiac transplant recipients and patients with dialysis-independent or dialysis-dependent chronic renal failure. Clin Sci 1992;83:437-44.
17. [17] Sagnella GA, Markandu ND, Buckley MG, et al. ANP-cyclic GMP relationships in normal humans - Effects of dietary sodium intake. Clin Sci 1993;83:13-7.
18. [18] Siegel S, Castellan NJ, Nonparametric statistics for the behavioural sciences, second edition. New York: McGraw-Hill, 1988.
19. [19] Afifi AA, Azen SP, Statistical analysis. A computer oriented approach. second edition. New York Academic Press, 1979.
20. [20] Woods RL. Contribution of the kidney to metabolic clearance of atrial natriuretic peptide. Am J Physiol 1988;255:E934-41.
21. [21] Raine AE, Erne P, Burgisser E, et al. Atrial natriuretic peptide and atrial pressure in patients with congestive heart failure. N Engl J Med 1986;315:533-7.
22. [22] Hirata Y, Ishii M, Matsuoka H, et al. Plasma concentrations of alpha-human atrial natriuretic polypeptide and cyclic GMP in patients with heart disease. Am Heart J 1987;113:463-9.
23. [23] Fujio N, Ohasho M, Nawata H, et al. Relationship between atrial natriuretic polypeptide and cyclic 3′5′-guanosine monophosphate in human plasma. J Lab Clin Med 1987;109:706-10.
24. [24] Bacay AC, Mantyh CR, Cohen AH, et al. Glomerular atrial natriuretic factor receptors in primary glomerulopathies: studies in human renal biopsies. Am J Kidney Dis 1989;14:386-95.
25. [25] Siragy HM, Johns RA, Peach MJ, et al. Nitric oxide alters renal function and guanosine 3′-5′-cyclic monophosphate. Hypertension 1992;19:775-9.
26. [26] Wilkins MR, Settle SL, Needleman P. Augmentation of the natriuretic activity of exogenous and endogenous atriopeptin in rats by inhibition of cyclic GMP degradation. J Clin Invest 1990;85:1274-9.
27. [27] Holmes SJ, Espiner EA, Richards AM, et al. Renal, endocrine, and haemodynamic interactions of human brain natriuretic peptide in normal man. J Clin Endocrinol Metab 1993;76:91-6.
28. [28] Carstens J, Jensen KT, Pedersen EB. Effect of urodilatin infusion on renal haemodynamics, tubular function and vasoactive hormones. Clin Sci 1997;92:397-407.